HK1199040A1 - 抗體用途 - Google Patents

抗體用途

Info

Publication number
HK1199040A1
HK1199040A1 HK14112443.2A HK14112443A HK1199040A1 HK 1199040 A1 HK1199040 A1 HK 1199040A1 HK 14112443 A HK14112443 A HK 14112443A HK 1199040 A1 HK1199040 A1 HK 1199040A1
Authority
HK
Hong Kong
Prior art keywords
antibody
Prior art date
Application number
HK14112443.2A
Other languages
English (en)
Inventor
Fulvio Dacquisto
Mauro Perretti
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of HK1199040A1 publication Critical patent/HK1199040A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
HK14112443.2A 2011-12-14 2014-12-10 抗體用途 HK1199040A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201121564A GB201121564D0 (en) 2011-12-14 2011-12-14 Use of antibody
PCT/GB2012/000906 WO2013088111A1 (en) 2011-12-14 2012-12-14 Use of antibody

Publications (1)

Publication Number Publication Date
HK1199040A1 true HK1199040A1 (zh) 2015-06-19

Family

ID=45560502

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112443.2A HK1199040A1 (zh) 2011-12-14 2014-12-10 抗體用途

Country Status (7)

Country Link
US (2) US10752677B2 (zh)
EP (1) EP2791167B1 (zh)
JP (1) JP6406642B2 (zh)
ES (1) ES2670999T3 (zh)
GB (1) GB201121564D0 (zh)
HK (1) HK1199040A1 (zh)
WO (1) WO2013088111A1 (zh)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules
GB201813137D0 (en) 2018-08-10 2018-09-26 Medannex Ltd Cancer treatment with an antibody
JP7224628B2 (ja) * 2019-02-01 2023-02-20 国立研究開発法人産業技術総合研究所 抗ｍｃ１６抗体
GB201904717D0 (en) * 2019-04-03 2019-05-15 Univ London Queen Mary Treatment and diagnosis of mental disorders
WO2023089150A1 (en) 2021-11-18 2023-05-25 Medannex Ltd. Combination therapy for cancer

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
GB8625941D0 (en) * 1986-10-30 1986-12-03 Sandoz Ltd Substituted alpha-amino acids
US5051364A (en) 1989-02-16 1991-09-24 The Salk Institute For Biological Studies Anti-lipocortin-I and anti-lipocortin-II monoclonal antibodies
US5565338A (en) 1990-06-04 1996-10-15 La Jolla Institute For Allergy And Immunology Suppressor T-cell hybridoma and production of allergen specific glycosylation inhibiting factor
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
JP3720353B2 (ja) 1992-12-04 2005-11-24 メディカル リサーチ カウンシル 多価および多重特異性の結合タンパク質、それらの製造および使用
WO2003057715A2 (en) 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
CN1726395A (zh) 2002-12-17 2006-01-25 北京诺赛基因组研究中心有限公司 胰腺癌的特异标记
US8198020B2 (en) 2003-08-22 2012-06-12 Potentia Pharmaceuticals, Inc. Compositions and methods for enhancing phagocytosis or phagocyte activity
WO2005027965A1 (en) 2003-09-24 2005-03-31 Peter Krammer Antibodies against annexins, use thereof for therapy and diagnosis. use of annexins for therapy and diagnosis.
WO2005117848A2 (en) 2004-06-02 2005-12-15 Sidney Kimmel Cancer Center Vascular targets for detecting, imaging and treating neoplasia or neovasculature
MX2008015037A (es) 2006-05-26 2008-12-10 Eisai R&D Man Co Ltd Compuestos de imidazoazepinona.
GB0822011D0 (en) 2008-12-02 2009-01-07 Queen Mary & Westfield College Treatment
BR112012031107A2 (pt) 2010-06-09 2017-07-25 Queen Mary & Westfield College molécula de ligação específica cultivada contra a proteína anx-a1 humana, linha de células de hibridoma, composição farmacêutica , uso da molécula de ligação específica e método para o tratamento de uma doença mediada por linfócitos t em um indivíduo com necessidade do mesmo
US20130088110A1 (en) * 2011-10-07 2013-04-11 Michael Charles Bertsch SMT System
GB201121561D0 (en) * 2011-12-14 2012-01-25 Queen Mary & Westfield College Transgenic animal
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
JP2016197324A (ja) * 2015-04-03 2016-11-24 キヤノン株式会社 情報処理装置、情報処理装置の制御方法、及びプログラム
GB201702091D0 (en) 2017-02-08 2017-03-22 Medannex Ltd Specific binding molecules

Also Published As

Publication number Publication date
US10752677B2 (en) 2020-08-25
ES2670999T3 (es) 2018-06-04
EP2791167B1 (en) 2018-02-14
EP2791167A1 (en) 2014-10-22
JP2015501829A (ja) 2015-01-19
WO2013088111A1 (en) 2013-06-20
US20210079076A1 (en) 2021-03-18
GB201121564D0 (en) 2012-01-25
JP6406642B2 (ja) 2018-10-17
US20150004164A1 (en) 2015-01-01

Similar Documents

Publication Publication Date Title
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
HK1255608A1 (zh) 抗htra1抗體及使用方法
IL259826A (en) Anti-alphabetatisiar antibody
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
IL229254A0 (en) Therapeutic antibodies
ZA201403760B (en) Anti-cd98 antibodies and methods of use thereof
HK1201843A1 (zh) 抗聚泛素抗體及使用方法
HK1199842A1 (zh) 抗涎免凝集素- 抗體及其用途
TWI563004B (en) Anti-hxcr1 antibody
HK1200839A1 (zh) 雙特異性 細胞活化劑抗體
HK1199040A1 (zh) 抗體用途
EP2684869A4 (en) PREPARATION OF 3-MERCAPOTOPROPIONATES
EP2714713A4 (en) PURIFICATION OF ANTIBODIES
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
EP2714074A4 (en) ANTIBODIES AGAINST EMR1
ZA201308992B (en) Therapeutic antibodies
GB201105866D0 (en) This is about me